Mural Oncology’s First Virtual Investor Day to Highlight Late-Stage Clinical Progress
26. September 2024 07:00 ET
|
Mural Oncology, Inc.
Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for platinum-resistant ovarian cancer and Q2 2025 for mucosal...
Mural Oncology Appoints Veteran Business Development Executive George Golumbeski, Ph.D., to its Board of Directors
31. Juli 2024 07:00 ET
|
Mural Oncology, Inc.
WALTHAM, Mass and DUBLIN, July 31, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine...
Global Protein Expression Market Report 2024-2032
12. Juni 2024 10:51 ET
|
Research and Markets
Dublin, June 12, 2024 (GLOBE NEWSWIRE) -- The "Global Protein Expression Market Report by Product, Application, End User, and Region 2024-2032" report has been added to ResearchAndMarkets.com's...
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23. Mai 2024 17:00 ET
|
Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Mural Oncology Announces First Quarter 2024 Financial Results and Provides Business Update
14. Mai 2024 07:00 ET
|
Mural Oncology, Inc.
Mural Oncology reiterates cash runway projection into 4Q 2025, with sufficient capital to fund key clinical readouts.
Mural Oncology Presents Preclinical Data for IL-18 and IL-12 Programs at the 2024 American Association for Cancer Research Annual Meeting
09. April 2024 16:00 ET
|
Mural Oncology, Inc.
Mural Oncology, a clinical-stage immuno-oncology company, shared pre-clinical data from its Interleukin-18 (IL-18) and IL-12 programs at AACR today.
Cancer Cachexia Global Strategic Research Report 2024: Market to Reach $3.5 Billion by 2030, Driven by Promising Treatment Options
05. April 2024 09:27 ET
|
Research and Markets
Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Cancer Cachexia - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Cancer Cachexia Market to Reach...
Global Cytokine Market Anticipated to Surge, Exhibiting a 7.44% CAGR Through 2028
29. März 2024 05:38 ET
|
Research and Markets
Dublin, March 29, 2024 (GLOBE NEWSWIRE) -- The "Global Cytokine Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's...
Mural Oncology Announces Enhancements to Late-Stage Clinical Trials
08. Januar 2024 07:00 ET
|
Mural Oncology, Inc.
Strategic changes to ARTISTRY-6 and ARTISTRY-7, both potentially registrational trials of nemvaleukin, are intended to result in more clinically meaningful dataMural intends to nominate development...
Adjuvants Market Size to be Worth USD 7.9 billion by 2031, at a CAGR of 6.7%| Transparency Market Research, Inc.
01. Dezember 2023 10:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global adjuvants market is estimated to flourish at a CAGR of 6.7% from 2022 to 2031....